You are here: Industry Insights > CNS

News List

Cyclerion Announces Positive Data from CNS Translational Study in Healthy Elderly Subjects americanpharmaceuticalreview
October 21, 2020
Cyclerion Therapeutics announced results from its Phase 1 translational pharmacology study of IW-6463, the first soluble guanylate cyclase (sGC) stimulator in clinical development for CNS disorders.
Sperogenix and Minoryx Enter Exclusive License Agreement contractpharma
September 24, 2020
Will develop and commercialize leriglitazone in mainland China, Hong Kong, S.A.R., China and Macau, S.A.R., China.
Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong, S.A.R., China and Macau, S.A.R., China prnasia
September 23, 2020
Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition.
Smart biomaterial drug delivery system could improve CNS injury recovery europeanpharmaceuticalreview
September 21, 2020
The implanted biomaterial drug delivery system releases methylprednisolone and reduces inflammation, promoting central nervous system (CNS) repair.
CNS Achieves Key Milestones in Berubicin Dual-track Mfg. Strategy contractpharma
September 07, 2020
CNS and Pii complete successful lab simulation of the lyophilization cycle and Pii is expected to begin manufacturing Berubicin during 3Q20.
Lilly signs up for access to Evox' tech in R&D deal pharmatimes
June 16, 2020
Evox Therapeutics has signed a collaboration deal with Eli Lilly centred on brain/CNS disorders, which could net the latter around $1.2 billion in development, regulatory and commercial milestone payments.
Researchers decode neurological symptoms of coronavirus infection expresspharma
June 01, 2020
The scientists said further studies involving brain scans and testing of CNS tissue will be crucial to understanding the biological process of the disease in the nervous system.
CNS Announces Filing of Orphan Drug Designation for Brain Cancer Drug americanpharmaceuticalreview
April 26, 2020
CNS Pharmaceuticals has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its lead product Berubicin.
Ten drugs in pre-registration likely to be blockbusters by 2025, finds report europeanpharmaceuticalreview
March 11, 2020
New research has found that of the drugs in the pre-registration phase, 10 are expected to become blockbusters over the next six years.
Severe Adverse Cardiovascular Events Associated With Ibrutinib drugs
September 27, 2019
Cardiovascular adverse drug reactions (CV-ADR) occur in association with ibrutinib, according to a study published in the issue of the Journal of the American College of Cardiology.

Previous page 1 2 3 Next page